Roche’s Gantenerumab May Rise From The Alzheimer’s Ashes
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma has renewed interest in the anti-amyloid beta antibody – which failed a large Phase III trial - after Biogen released positive early data on a similar rival compound.
You may also be interested in...
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
Roche Says Kadcyla Fails To Better Herceptin In First-Line Breast Cancer
Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.